How to buy VBI Vaccines shares | US$3.36

Own your own VBIV stock in just a few minutes.

Posted

Fact checked

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.

US$3.36
current price
US$0.59
change
21.3%
change %

How to buy stock in VBI Vaccines

  1. Compare share trading platforms. To buy shares in a US company from New Zealand you’ll need to find a trading platform that offers access to US stock markets. If you’re just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, including your ID. Fund your account with a bank transfer, credit card or debit card.
  3. Search for VBI Vaccines. Find the share by name or ticker symbol: VBIV. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until VBI Vaccines reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At today's price of US$3.36, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of VBI Vaccines, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of VBI Vaccines. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
  7. Price details for VBI Vaccines (VBIV)

    Open $2.9 Previous close $2.77
    High $3.54 Change $0.59
    Low $2.8701 Change % 21.3%
    Close $3.36 Timestamp 1594152000
    Volume N/A GMT offset 0

    VBI Vaccines stock price

    Use our graph to track the performance of VBIV stocks over time.

    Compare share trading platforms

    Data indicated here is updated regularly
    Name Product Monthly fee Currency conversion fee Available markets
    Stake
    $0
    1% ($2 min)
    NASDAQ
    NYSE
    BATS
    Chicago Stock Exchange
    And more
    Sign up through Finder and use referral code "FINDERNZ" for a free stock. Trade 3,500 US listed stocks and ETFs through Stake with $0 brokerage.
    loading

    Compare up to 4 providers

    The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

    VBI Vaccines company summary

    Information last updated 2020-06-25.

    VBI Vaccines (VBIV) is a leading Biotechnology business based in the USA. VBI Vaccines (VBIV) is listed on the NASDAQ and employs 123 staff.

    Profile

    Industry Biotechnology Currency symbol $
    Code VBIV Country name USA
    Type Common Stock Country ISO US
    Name VBI Vaccines Inc ISIN US91822J1034
    Exchange NASDAQ CUSIP 91822J103
    Currency code USD Sector Healthcare
    Currency name US Dollar Full-time employees 123

    Detailed company information

    VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology in Israel, the United States, and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for a functional cure of chronic hepatitis B. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the target virus to elicit a potent immune response. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. In addition, the company engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It primarily serves physicians and pharmacists through direct sales. VBI Vaccines Inc. has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. It also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.

    Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
Go to site